| CAS NO. |
Products Name |
|
|
|
|
|
|
| 686347-12-6 |
Otenabant (CP-945598) HCl |
more... |
| Otenabant (CP-945598) HCl is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor. Phase 1. |
|
| 95809-78-2 |
CPI-613 |
more... |
| CPI-613, a lipoate analog, inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts tumor cell mitochondrial metabolism. Phase 2. |
|
|
|
|
|
| 231277-92-2 |
Lapatinib |
more... |
| Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
|
| 154447-36-6 |
LY294002 |
more... |
| LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. |
|
|
|
| 1254473-64-7 |
LY2874455 |
more... |
| LY2874455 is a novel and potent FGF/FGFR Inhibitor. LY2874455 exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship. |
|
| 635318-11-5 |
LY404039 |
more... |
| LY404039 is a potent agonist of recombinant human mGlu2/mGlu3 receptors with Ki of 149 nM/92 nM, shows >100-fold selectivity over ionotropic glutamate receptors, glutamate transporters, and other receptors. Phase 3. |
|
All Products
